# IQVIA

> IQVIA combines contract clinical research, healthcare data, analytics, consulting and life-sciences software in one global company. Pharmaceutical, biotech, medical-device, payer, provider and public-sector customers use it to design and operate trials, understand treatment patterns, manage safety and regulatory work, and commercialize therapies. Its central advantage is the connection between an unusually broad healthcare-data estate and the people and systems that execute work across the medicine lifecycle.

- **Founded:** 2016
- **Headquarters:** Durham, United States
- **Founders:** Dennis Gillings (Founder of legacy company Quintiles), Bill Frohlich (Co-founder of legacy company IMS Health), David Dubow (Co-founder of legacy company IMS Health)
- **Team size:** Approximately 93,000 employees in more than 100 countries as of year-end 2025
- **Products:** Research & Development Solutions, Commercial Solutions, Real World Evidence, Safety, Regulatory, Quality and Medical Information, IQVIA.ai
- **Notable:** Ranked No. 1 in Fortune’s Health Care: Pharmacy and Other Services category for a fifth consecutive year in 2026 and included on the World’s Most Admired Companies list for a ninth consecutive year., Reported 2025 revenue of $16.31 billion, adjusted EBITDA of $3.788 billion and free cash flow of $2.051 billion., Reached a $34.2 billion R&D Solutions contracted backlog at June 30, 2026.

## Products & services

- **Research & Development Solutions** — Clinical-development services spanning study design, site identification, trial execution, patient recruitment, laboratories, eCOA, IRT and clinical data analytics.
- **Commercial Solutions** — Data, consulting, market access, brand strategy, omnichannel engagement, field-force support and software used to launch and manage healthcare products.
- **Real World Evidence** — Curated health data, observational research, evidence networks, health economics and analytics used to study safety, effectiveness, access and outcomes outside controlled trials.
- **Safety, Regulatory, Quality and Medical Information** — Technology-enabled pharmacovigilance, regulatory information management, quality systems, commercial compliance and medical-information operations.
- **IQVIA.ai** — A unified agentic AI platform for clinical, commercial and real-world life-sciences workflows, built with NVIDIA technology and designed for regulated healthcare settings.
- **Healthcare-grade AI** — IQVIA’s governance and engineering approach for AI systems requiring healthcare-specific precision, privacy, safety, scalability and regulatory controls.
- **Enterprise information management** — Cloud software and services for data integration, master data management, governance, bridging and self-service analytics.
- **Contract Sales & Medical Solutions** — Outsourced field sales, medical teams and patient-support capabilities for life-sciences manufacturers.

## Achievements

- Ranked No. 1 in Fortune’s Health Care: Pharmacy and Other Services category for a fifth consecutive year in 2026 and included on the World’s Most Admired Companies list for a ninth consecutive year.
- Reported 2025 revenue of $16.31 billion, adjusted EBITDA of $3.788 billion and free cash flow of $2.051 billion.
- Reached a $34.2 billion R&D Solutions contracted backlog at June 30, 2026.
- Received the 2025 WCG Pinnacle Award for site relationships in professionalism and communication, based on a survey with more than 12,000 participants.
- IQVIA Health Research Space won the 2025 MedTech Breakthrough Award for Best Mobile App for Patient Engagement.
- IQVIA IRT SAVE received a 2026 Silver Stevie Award in the Health & Pharmaceuticals product category.
- SmartSolve eQMS received a 2025 Bronze Stevie Award for healthcare technology and is used by more than one million professionals, according to IQVIA.

## Latest updates

- **2026-07** — Reported second-quarter revenue of $4.368 billion, up 8.7% year over year, and raised full-year 2026 revenue guidance to $17.275-$17.475 billion.
- **2026-05** — Expanded its strategic collaboration with Kexing Biopharm for AI-enabled global biosimilar development.
- **2026-05** — IQVIA IRT SAVE won a Silver Stevie Award for innovation in clinical supply management.
- **2026-03** — Launched IQVIA.ai, a unified agentic AI platform powered by NVIDIA technology.
- **2026-02** — Signed an agreement to acquire drug-discovery assets from Charles River Laboratories, expanding early-stage capabilities.
- **2026-02** — Announced a strategic collaboration with Duke Clinical Research Institute in obesity and related clinical research.
- **2026-01** — Announced a long-term commercial data-foundation collaboration with Boehringer Ingelheim.

## Links

- Website: https://www.iqvia.com/
- LinkedIn: https://www.linkedin.com/company/iqvia
- Twitter/X: https://twitter.com/IQVIA_global
- YouTube: https://www.youtube.com/@IQVIA
- Facebook: https://www.facebook.com/IQVIA/

---

Profile page: https://yespress.io/iqvia
Published by YesPress — https://yespress.io
Last updated: 2026-08-13